Searched for: school:SOM
Department/Unit:Population Health
Core outcome sets for trials of interventions to prevent and to treat multimorbidity in adults in low and middle-income countries: the COSMOS study
Vidyasagaran, Aishwarya Lakshmi; Ayesha, Rubab; Boehnke, Jan R; Kirkham, Jamie; Rose, Louise; Hurst, John R; Miranda, Juan Jaime; Rana, Rusham Zahra; Vedanthan, Rajesh; Faisal, Mehreen Riaz; Afaq, Saima; Agarwal, Gina; Aguilar-Salinas, Carlos Alberto; Akinroye, Kingsley; Akinyemi, Rufus Olusola; Ali, Syed Rahmat; Aman, Rabeea; Anza-Ramirez, Cecilia; Appuhamy, Koralagamage Kavindu; Baldew, Se-Sergio; Barbui, Corrado; Batista, Sandro Rogerio Rodrigues; Caamaño, MarÃa Del Carmen; Chowdhury, Asiful Haidar; de Siqueira-Filha, Noemia Teixeira; Del Castillo Fernández, Darwin; Downey, Laura; Flores-Flores, Oscar; GarcÃa, Olga P; GarcÃa-Ulloa, Ana Cristina; Holt, Richard Ig; Huque, Rumana; Kabukye, Johnblack K; Kanan, Sushama; Khalid, Humaira; Koly, Kamrun Nahar; Kwashie, Joseph Senyo; Levitt, Naomi S; Lopez-Jaramillo, Patricio; Mohan, Sailesh; Muliyala, Krishna Prasad; Naz, Qirat; Odili, Augustine Nonso; Oyeyemi, Adewale L; Pacheco-Barrios, Niels Victor; Praveen, Devarsetty; Purgato, Marianna; Ronquillo, Dolores; Siddiqi, Kamran; Singh, Rakesh; Tran, Phuong Bich; Tufail, Pervaiz; Uphoff, Eleonora P; van Olmen, Josefien; Verhey, Ruth; Wright, Judy M; Zafra-Tanaka, Jessica Hanae; Zavala, Gerardo A; Zhao, Yang William; Siddiqi, Najma; ,
INTRODUCTION/BACKGROUND:The burden of multimorbidity is recognised increasingly in low- and middle-income countries (LMICs), creating a strong emphasis on the need for effective evidence-based interventions. Core outcome sets (COS) appropriate for the study of multimorbidity in LMICs do not presently exist. These are required to standardise reporting and contribute to a consistent and cohesive evidence-base to inform policy and practice. We describe the development of two COS for intervention trials aimed at preventing and treating multimorbidity in adults in LMICs. METHODS:To generate a comprehensive list of relevant prevention and treatment outcomes, we conducted a systematic review and qualitative interviews with people with multimorbidity and their caregivers living in LMICs. We then used a modified two-round Delphi process to identify outcomes most important to four stakeholder groups (people with multimorbidity/caregivers, multimorbidity researchers, healthcare professionals and policymakers) with representation from 33 countries. Consensus meetings were used to reach agreement on the two final COS. REGISTRATION/BACKGROUND:https://www.comet-initiative.org/Studies/Details/1580. RESULTS:The systematic review and qualitative interviews identified 24 outcomes for prevention and 49 for treatment of multimorbidity. An additional 12 prevention and 6 treatment outcomes were added from Delphi round 1. Delphi round 2 surveys were completed by 95 of 132 round 1 participants (72.0%) for prevention and 95 of 133 (71.4%) participants for treatment outcomes. Consensus meetings agreed four outcomes for the prevention COS: (1) adverse events, (2) development of new comorbidity, (3) health risk behaviour and (4) quality of life; and four for the treatment COS: (1) adherence to treatment, (2) adverse events, (3) out-of-pocket expenditure and (4) quality of life. CONCLUSION/CONCLUSIONS:Following established guidelines, we developed two COS for trials of interventions for multimorbidity prevention and treatment, specific to adults in LMIC contexts. We recommend their inclusion in future trials to meaningfully advance the field of multimorbidity research in LMICs. PROSPERO REGISTRATION NUMBER/UNASSIGNED:CRD42020197293.
PMID: 39160083
ISSN: 2059-7908
CID: 5680492
Medical Expertise - Balancing Science, Values, and Trust
Lerner, Barron H
PMID: 39132942
ISSN: 1533-4406
CID: 5697072
Cardiometabolic Comorbidity Burden and Circulating Biomarkers in Patients with Chronic Coronary Disease in the ISCHEMIA Trials
Hamo, Carine E; Liu, Richard; Wu, Wenbo; Anthopolos, Rebecca; Bangalore, Sripal; Held, Claes; Kullo, Ifitkhar; Mavromatis, Kreton; McManus, Bruce; Newby, L Kristin; Reynolds, Harmony R; Ruggles, Kelly V; Wallentin, Lars; Maron, David J; Hochman, Judith S; Newman, Jonathan D; Berger, Jeffrey S; ,
Cardiometabolic comorbidities, diabetes (DM), hypertension (HTN), and obesity, contribute to cardiovascular disease (CVD). Circulating biomarkers facilitate prognostication for patients with CVD. We explored the relationship between cardiometabolic comorbidity burden in patients with chronic coronary disease (CCD) and biomarkers of myocardial stretch, injury, inflammation, and platelet activity. We analyzed participants from the ISCHEMIA Trials biorepository with plasma biomarkers (NT-proBNP, hs-cTnT, hs-CRP, IL-6, sCD40L, and GDF-15) and clinical risk factors [hemoglobin A1c (HbA1c), systolic blood pressure (SBP), and body mass index (BMI)] at baseline. We defined cardiometabolic comorbidities as DM, HTN, and obesity at baseline. Comorbidity burden characterized by number and severity of comorbidities. Controlled comorbidities were defined as HbA1c <7% for those with DM, SBP <130 mmHg for those with HTN and BMI <30 kg/m2. Severely uncontrolled was defined as HbA1c ≥8%, SBP ≥160 mmHg, and BMI ≥35 kg/m2. We performed linear regression analyses to examine the association between comorbidity burden and log-transformed biomarker levels adjusting for age, sex, eGFR controlled for hemodialysis, and left ventricular ejection fraction. A total of 752 individuals (mean age 66, 19% female, 84% white) were included in this analysis. Self-reported Black race, current smokers, history of MI and HF had greater cardiometabolic comorbidity burden. The presence of ≥ 1 severely uncontrolled comorbidity was associated with significantly higher baseline levels of hs-cTnT, hs-CRP, IL-6, and GDF-15 compared to participants with no comorbidities. In conclusion, increasing cardiometabolic comorbidity burden in patients with CCD is associated with higher levels of circulating biomarkers of myocardial injury and inflammation.
PMID: 38844195
ISSN: 1879-1913
CID: 5665722
Evaluating the efficacy of UNav: A computer vision-based navigation aid for persons with blindness or low vision
Yang, Anbang; Tamkittikhun, Nattachart; Hamilton-Fletcher, Giles; Ramdhanie, Vinay; Vu, Thu; Beheshti, Mahya; Hudson, Todd; Vedanthan, Rajesh; Riewpaiboon, Wachara; Mongkolwat, Pattanasak; Feng, Chen; Rizzo, John-Ross
UNav is a computer-vision-based localization and navigation aid that provides step-by-step route instructions to reach selected destinations without any infrastructure in both indoor and outdoor environments. Despite the initial literature highlighting UNav's potential, clinical efficacy has not yet been rigorously evaluated. Herein, we assess UNav against standard in-person travel directions (SIPTD) for persons with blindness or low vision (PBLV) in an ecologically valid environment using a non-inferiority design. Twenty BLV subjects (age = 38 ± 8.4; nine females) were recruited and asked to navigate to a variety of destinations, over short-range distances (<200 m), in unfamiliar spaces, using either UNav or SIPTD. Navigation performance was assessed with nine dependent variables to assess travel confidence, as well as spatial and temporal performances, including path efficiency, total time, and wrong turns. The results suggest that UNav is not only non-inferior to the standard-of-care in wayfinding (SIPTD) but also superior on 8 out of 9 metrics, as compared to SIPTD. This study highlights the range of benefits computer vision-based aids provide to PBLV in short-range navigation and provides key insights into how users benefit from this systematic form of computer-aided guidance, demonstrating transformative promise for educational attainment, gainful employment, and recreational participation.
PMID: 39137956
ISSN: 1949-3614
CID: 5726822
"In the Village That She Comes from, Most of the People Don't Know Anything about Cervical Cancer": A Health Systems Appraisal of Cervical Cancer Prevention Services in Tanzania
Chelva, Melinda; Kaushal, Sanchit; West, Nicola; Erwin, Erica; Yuma, Safina; Sleeth, Jessica; Yahya-Malima, Khadija I; Shelley, Donna; Risso-Gill, Isabelle; Yeates, Karen
INTRODUCTION/BACKGROUND:Cervical cancer is the fourth most common cancer in women globally. It is the most common cancer in Tanzania, resulting in about 9772 new cases and 6695 deaths each year. Research has shown an association between low levels of risk perception and knowledge of the prevention, risks, signs, etiology, and treatment of cervical cancer and low screening uptake, as contributing to high rates of cervical cancer-related mortality. However, there is scant literature on the perspectives of a wider group of stakeholders (e.g., policymakers, healthcare providers (HCPs), and women at risk), especially those living in rural and semi-rural settings. The main objective of this study is to understand knowledge and perspectives on cervical cancer risk and screening among these populations. METHODS:We adapted Risso-Gill and colleagues' framework for a Health Systems Appraisal (HSA), to identify HCPs' perspective of the extent to which health system requirements for effective cervical cancer screening, prevention, and control are in place in Tanzania. We adapted interview topic guides for cervical cancer screening using the HSA framework approach. Study participants (69 in total) were interviewed between 2014 and 2018-participants included key stakeholders, HCPs, and women at risk for cervical cancer. The data were analyzed using reflexive thematic analysis methodology. RESULTS:Seven themes emerged from our analysis of semi-structured interviews and focus groups: (1) knowledge of the role of screening and preventive care/services (e.g., prevention, risks, signs, etiology, and treatment), (2) training and knowledge of HCPs, (3) knowledge of cervical cancer screening among women at risk, (4) beliefs about cervical cancer screening, (5) role of traditional medicine, (6) risk factors, and (7) symptoms and signs. CONCLUSIONS:Our results demonstrate that there is a low level of knowledge of the role of screening and preventive services among stakeholders, HCPs, and women living in rural and semi-rural locations in Tanzania. There is a critical need to implement more initiatives and programs to increase the uptake of screening and related services and allow women to make more informed decisions on their health.
PMCID:11353714
PMID: 39200668
ISSN: 1660-4601
CID: 5701592
Monitoring illicit pentobarbital availability in the United States: A National Drug Early Warning System briefing
Palamar, Joseph J; Fitzgerald, Nicole D; Goldberger, Bruce A; Cottler, Linda B
BACKGROUND:Pentobarbital is a Schedule II/III short-acting barbiturate with limited medical use in humans. Veterinary professionals use pentobarbital to euthanize dogs, cats, and other companion animals. Pentobarbital is also utilized in capital punishment and small amounts are illegally shipped or diverted to assist in suicides. However, five kilograms of pentobarbital smuggled in from Mexico was recently seized by an organized crime drug enforcement task force (along with fentanyl, heroin, and cocaine), which may suggest a shift in illicit supply. We investigated potential indicators of illicit pentobarbital use or availability in the US to help determine whether this drug is becoming an emerging public health concern. METHODS:The National Drug Early Warning System requested information on pentobarbital from its sentinel surveillance sites and collaborators and conducted a search of current literature. RESULTS:In early 2024, multiple batches of counterfeit pills (e.g., pressed as "M30s" to represent oxycodone) confiscated near the Southwest border tested positive for pentobarbital plus combinations of fentanyl, fentanyl analogs, and xylazine. Other indicators suggest pentobarbital is being smuggled in powder form and possibly sold as another drug such as heroin. One national drug analysis program detected pentobarbital in 217 drug submissions from 2020 to 2023, and there were at least 12 fatal exposures linked to use from 2020 to 2022. CONCLUSION/CONCLUSIONS:Continued monitoring of illicit use and availability is needed as pentobarbital may continue to appear on the illicit market. Unknown exposure can occur if the drug is mixed into counterfeit pills or sold in powder form represented to be another drug.
PMID: 39173219
ISSN: 1879-0046
CID: 5681002
Naturalistic patterns of sustained attention across early childhood: Developmental profiles and longitudinal associations with executive functions
Werchan, Denise M; Brandes-Aitken, Annie; Ku, Seulki; Blair, Clancy
The capacity to sustain attention over time develops rapidly over early childhood and is associated with socioemotional and cognitive outcomes. However, sustained attention has largely been studied in either shared or independent contexts, leading to gaps in our understanding of how trade-offs between sustained attention to shared versus individual targets may predict later outcomes. We examined this question in a longitudinal sample of 1,290 children (49% female, 43% Black), living in predominately rural, low-income regions, using a naturalistic shared picture book reading task. Children's sustained attention to individual relative to shared targets during the book reading task was measured at 24 and 35 months. Using latent profile analysis, we identified four developmental profiles of children's attentional trajectories: three of the profiles differed in the extent that children' attention shifted toward more socially directed relative to individually directed attention; a fourth profile showed atypical decreases in both socially directed and individually directed attention across development. Importantly, heterogeneity in children's attentional profiles were associated with differences in executive functions at 48 months of age. Specifically, children who showed greater relative increases in socially directed attention had higher executive functions performance, whereas children with atypical decreases in attention showed substantial deficits in this domain. These findings reveal distinct longitudinal patterns of sustained attention in naturalistic contexts and show that heterogeneity in these patterns are robust predictors of subsequent executive functions. This person-centered approach provides novel insights into how quantitative and qualitative changes in attention may impact executive functions development and may help identify children at risk for nonnormative trajectories. (PsycInfo Database Record (c) 2024 APA, all rights reserved).
PMID: 39133598
ISSN: 1939-0599
CID: 5711832
Biomarkers of Airway Disease, Barrett's and Underdiagnosed Reflux Noninvasively (BAD-BURN) in World Trade Center exposed firefighters: a case-control observational study protocol
Javed, Urooj; Podury, Sanjiti; Kwon, Sophia; Liu, Mengling; Kim, Daniel H; Fallahzadeh, Aida; Li, Yiwei; Khan, Abraham R; Francois, Fritz; Schwartz, Theresa; Zeig-Owens, Rachel; Grunig, Gabriele; Veerappan, Arul; Zhou, Joanna; Crowley, George; Prezant, David J; Nolan, Anna
BACKGROUND:Particulate matter exposure (PM) is a cause of aerodigestive disease globally. The destruction of the World Trade Center (WTC) exposed first responders and inhabitants of New York City to WTC-PM and caused obstructive airways disease (OAD), gastroesophageal reflux disease (GERD) and Barrett's Esophagus (BE). GERD not only diminishes health-related quality of life but also gives rise to complications that extend beyond the scope of BE. GERD can incite or exacerbate allergies, sinusitis, bronchitis, and asthma. Disease features of the aerodigestive axis can overlap, often necessitating more invasive diagnostic testing and treatment modalities. This presents a need to develop novel non-invasive biomarkers of GERD, BE, airway hyperreactivity (AHR), treatment efficacy, and severity of symptoms. METHODS:Our observational case-cohort study will leverage the longitudinally phenotyped Fire Department of New York (FDNY)-WTC exposed cohort to identify Biomarkers of Airway Disease, Barrett's and Underdiagnosed Reflux Noninvasively (BAD-BURN). Our study population consists of n = 4,192 individuals from which we have randomly selected a sub-cohort control group (n = 837). We will then recruit subgroups of i. AHR only ii. GERD only iii. BE iv. GERD/BE and AHR overlap or v. No GERD or AHR, from the sub-cohort control group. We will then phenotype and examine non-invasive biomarkers of these subgroups to identify under-diagnosis and/or treatment efficacy. The findings may further contribute to the development of future biologically plausible therapies, ultimately enhance patient care and quality of life. DISCUSSION/CONCLUSIONS:Although many studies have suggested interdependence between airway and digestive diseases, the causative factors and specific mechanisms remain unclear. The detection of the disease is further complicated by the invasiveness of conventional GERD diagnosis procedures and the limited availability of disease-specific biomarkers. The management of reflux is important, as it directly increases risk of cancer and negatively impacts quality of life. Therefore, it is vital to develop novel noninvasive disease markers that can effectively phenotype, facilitate early diagnosis of premalignant disease and identify potential therapeutic targets to improve patient care. TRIAL REGISTRATION/BACKGROUND:Name of Primary Registry: "Biomarkers of Airway Disease, Barrett's and Underdiagnosed Reflux Noninvasively (BADBURN)". Trial Identifying Number: NCT05216133 . Date of Registration: January 31, 2022.
PMID: 39123126
ISSN: 1471-230x
CID: 5678522
Prenatal organophosphate pesticide exposure and sex-specific estimated Fetal size
Medley, Eleanor A; Trasande, Leonardo; Naidu, Mrudula; Wang, Yuyan; Ghassabian, Akhgar; Kahn, Linda G; Long, Sara; Afanasyeva, Yelena; Liu, Mengling; Kannan, Kurunthachalam; Mehta-Lee, Shilpi S; Cowell, Whitney
Prenatal organophosphate (OP) pesticide exposure may be associated with reduced fetal growth, although studies are limited and have mixed results. We investigated associations between prenatal OP pesticide exposure and fetal size and modification by fetal sex. Maternal urinary concentrations of dialkyl phosphate (DAP) metabolites were measured at three time points. Fetal biometrics were obtained from ultrasounds in the second (n=773) and third (n=535) trimesters. Associations between pregnancy-averaged ΣDAP and fetal biometry z-scores were determined through multiple linear regression. Modification by sex was investigated through stratification and interaction. In the second trimester, one ln-unit increase in ΣDAP was associated with lower estimated fetal weight (-0.15 SD; 95% CI: -0.29, -0.01), head circumference (-0.11 SD; CI: -0.22, 0.01), biparietal diameter (-0.14 SD; CI: -0.27, -0.01), and abdominal circumference (-0.12 SD; CI: -0.26, 0.01) in females. In the third trimester, one ln-unit increase in ΣDAP was associated with lower head circumference (-0.14 SD; CI: -0.28, 0.00) and biparietal diameter (-0.12 SD; CI: -0.26, 0.03) in males. Our results suggest that prenatal OP pesticide exposure is negatively associated with fetal growth in a sex-specific manner, with associations present for females in mid-gestation and males in late gestation.
PMID: 39117571
ISSN: 1476-6256
CID: 5679072
Obstructive Sleep Apnea, Platelet Aggregation, and Cardiovascular Risk
Kovbasyuk, Zanetta; Ramos-Cejudo, Jaime; Parekh, Ankit; Bubu, Omonigho M; Ayappa, Indu A; Varga, Andrew W; Chen, Ming-Huei; Johnson, Andrew D; Gutierrez-Jimenez, Eugenio; Rapoport, David M; Osorio, Ricardo S
BACKGROUND:Although related, the precise mechanisms linking obstructive sleep apnea (OSA) and cardiovascular disease (CVD) are unclear. Platelets are mediators of CVD risk and thrombosis and prior studies suggested associations of OSA and platelet activity. The aim of this study is to assess the link between OSA, platelet activity, and CVD-related risk factors. METHODS AND RESULTS/RESULTS:=0.002). No associations were detected in nonaspirin users (n=417). CONCLUSIONS:No associations were detected between OSA and platelet aggregation in a community sample. Our finding that OSA associates with increased platelet aggregation in the aspirin group, most of whom use it for primary prevention of CVD, suggests that platelet aggregation may mediate the adverse impact of OSA on vascular health in individuals with existing CVD risk, supporting further investigation.
PMID: 39056328
ISSN: 2047-9980
CID: 5696172